Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma
Study of Antibody Drug in Patients with Advanced Renal Cell Carcinoma
Sponsor: BMS
Enrolling: Male and Female Patients
IRB Number: AAAR3743
U.S. Govt. ID: NCT03117309
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: This research study is a phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational treatment to learn whether the intervention works in treating a specific disease. Investigational means that the intervention is being studied. The Food and Drug Administration (FDA) has approved Nivolumab as treatment for advanced renal cell carcinoma, however discontinuation of nivolumab and the combination with Ipilimumab are investigational. Nivolumab is an antibody (type of human protein) drug that may stimulate your body's immune system to fight tumor cells. Ipilimumab is also an antibody that may stimulate your body's immune system to fight tumor cells. Ipilimumab is FDA approved for the treatment of melanoma (skin cancer) and has been previously studied in renal cell cancer. Specifically, this study will look at the use of these treatments based on how your disease responds to the treatment. Both of these study drugs are given by IV (intravenous), through a vein.
This study is closed
Mark Stein, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with with advanced renal cell carcinoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator